Compare PRGO & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | BLFS |
|---|---|---|
| Founded | 1887 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2013 | 2013 |
| Metric | PRGO | BLFS |
|---|---|---|
| Price | $14.08 | $37.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $16.50 | ★ $31.29 |
| AVG Volume (30 Days) | ★ 2.4M | 760.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.86% | N/A |
| EPS Growth | N/A | ★ 77.27 |
| EPS | N/A | ★ 0.94 |
| Revenue | $800,000.00 | ★ $96,214,000.00 |
| Revenue This Year | N/A | $19.76 |
| Revenue Next Year | $0.74 | $17.03 |
| P/E Ratio | ★ N/A | $41.62 |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $9.23 | $17.86 |
| 52 Week High | $22.65 | $39.76 |
| Indicator | PRGO | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 64.77 |
| Support Level | $13.37 | $34.38 |
| Resistance Level | $15.06 | N/A |
| Average True Range (ATR) | 0.61 | 0.91 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 62.60 | 78.83 |
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.